The Tisch Cancer Institute (TCI) Human Immune Monitoring Core Shared Resource Facility (HIMCSRF) provides TCI members access to a comprehensive suite of immune monitoring assays allowing for the quantification of circulating proteins and immune cell characterization, along with spatial organization in tissues to support basic science, clinical, and translational studies. This is achieved by balancing innovation with robust protocols and operating procedures to ensure data quality and reproducibility with dedicated platforms for biospecimen processing and sample management, soluble factor profiling, phenotypic and functional immune cell characterization, immunogenomics, single cell transcriptomics, and multiplexed tissue imaging. The HIMCSRF is comprised of over twenty full time experts who specialize in characterizing immune profiles and responses across a diverse range of disease settings. The HIMC currently supports over 45 federal and foundation funded projects across a diverse range of clinical areas including cancer, and also serves as a central analysis hub for several multi-institutional consortia including the NIH Human Immunology Project Consortium (HIPC). The HIMCSRF is also an NCI-designated Cancer Immune Monitoring and Analysis Center (CIMAC) as part of a U24 consortium funded through the Cancer Moonshot program, and also actively supports 13 industry-sponsored research collaborations. Since its inception in 2011, the HIMCSRF contributed to the TCI?s mission by providing state-of-the-art technologies, project development, consistency, interpretations, and cost-effectiveness to all TCI programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA196521-06
Application #
10022661
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2015-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Laganà, A; Perumal, D; Melnekoff, D et al. (2018) Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. Leukemia 32:120-130
Scarborough, Bethann M; Smith, Cardinale B (2018) Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin 68:182-196
Chiang, David; Chen, Xintong; Jones, Stacie M et al. (2018) Single-cell profiling of peanut-responsive T cells in patients with peanut allergy reveals heterogeneous effector TH2 subsets. J Allergy Clin Immunol 141:2107-2120
D'Avola, Delia; Villacorta-Martin, Carlos; Martins-Filho, Sebastiao N et al. (2018) High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. Sci Rep 8:11570
Serasinghe, Madhavika N; Gelles, Jesse D; Li, Kent et al. (2018) Dual suppression of inner and outer mitochondrial membrane functions augments apoptotic responses to oncogenic MAPK inhibition. Cell Death Dis 9:29
Abbate, Franco; Badal, Brateil; Mendelson, Karen et al. (2018) FBXW7 regulates a mitochondrial transcription program by modulating MITF. Pigment Cell Melanoma Res :
Linde, Nina; Casanova-Acebes, Maria; Sosa, Maria Soledad et al. (2018) Macrophages orchestrate breast cancer early dissemination and metastasis. Nat Commun 9:21
Sonoshita, Masahiro; Scopton, Alex P; Ung, Peter M U et al. (2018) A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Nat Chem Biol 14:291-298
Hirschfield, Hadassa; Bian, C Billie; Higashi, Takaaki et al. (2018) In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment. Exp Mol Med 50:e419
Rattay, T; Symonds, R P; Shokuhi, S et al. (2018) The Patient Perspective on Radiogenomics Testing for Breast Radiation Toxicity. Clin Oncol (R Coll Radiol) 30:151-157

Showing the most recent 10 out of 143 publications